ACCELERATION OF STRATEGIC DEPLOYMENT
IN THE FIRST HALF OF 2023
- Strong growth in half-year core business revenues, up 37%
- Successful deployment of the Group's strategy:
- Share of proprietary products up, at 30% of revenues
- Continued internationalization, with 35% of revenues now generated outside of
France
- Acquisition of DID in
Italy effective as ofJuly 1 st, 2023
Strong growth of core business at +37%
In H1 2022, the Group generated sales of €83.6 million. Excluding non-recurring sales from the COVID business (€40.6m), growth for H1 2023 therefore reached +37%.
On a comparable proforma basis, i.e. excluding perimeter effects linked to acquisitions and non-recurring items1, growth of the core business remained dynamic, at +7%.
in €m | H1 2022 | H1 2023 | change. / core | at constant scope | |||||
TOTAL | COVID | core | |||||||
Revenues | 83.6 | 40.6 | 43.0 | 59.1 | +37% | +7% | |||
unaudited |
Successful deployment of the Group's strategy
The Group is successfully pursuing its strategy of targeted geographic and technological expansion, with the ambition of becoming a major international company in the specialty diagnostics market, providing its customers with a comprehensive molecular diagnostics offering, including its own solutions and those of its partners.
- Share of proprietary products reached 30% of revenues
The share of proprietary products increased to a high level, representing 30% of revenues (compared to 18% of core revenues in 2022), thanks in particular to the contribution of GenDx, consolidated in the Group's financial statements as of
- Continued international expansion of the Group
International sales are growing fast, representing 35% of first-half revenues (against 25% of core business revenues in 2022). This increase is mainly due to the new acquisitions made over the past year in
A new international entity joined the Group on
Outlook
With the confirmation of the strategic priorities chosen over the last few years, the
The Group is also pursuing the integration of its subsidiaries, and has recently made changes to its governance by setting up a Group Executive Committee.
Next financial meeting
H1 2023 results :
About For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Groupe Eurobio Scientific Anne-Sophie Hérelle, Deputy CEO Finance & IT Tel. +33(0) 1 69 79 64 80 | Calyptus Investors Relations Tel. +33(1) 53 65 68 68 - eurobio-scientific@calyptus.net |
1 Acquisitions of BMD Belgium in
Attachment
- 230724_PR_Eurobio-Scientific_CA_S1_23_EN_DEF
© OMX, source